Company intelligence / Profile preview

Aspis Biopharmaceutical

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

Aspis Biopharmaceutical was an early-stage biotechnology startup co-founded by researchers from the University of Southern California (USC) Keck School of Medicine. The company was established to develop disintegrin-based diagnostic and therapeutic solutions derived from snake venom. Its lead candidate, Vicrostatin (VCN), is a recombinant chimeric disintegrin designed to target multiple integrins (including alpha-V beta-3, alpha-V beta-5, and alpha-5 beta-1) to inhibit tumor angiogenesis, metastasis, and progression. The technology was later transitioned to Applied Integrin Sciences, which has since ceased operations.

Therapeutic areas: Oncology
Modalities: Recombinant proteinBiologicPeptides
Industry: Biotech

Beyond the preview

Go deeper on Aspis Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspis Biopharmaceutical.

Explore the full profile